title: Management of nicotinamide N-methyltransferase overexpression: inhibit the enzyme or reduce nicotinamide intake? Reply to Zhou S, Li D, Zhou Y [letter].
authors.affiliation: Sanofi Research and Development, Industriepark Hoechst, H824, D-65926, Frankfurt am Main, Germany, aimo.kannt@sanofi.com.
authors.forename: Aimo
authors.initials: A
authors.lastname: Kannt
authors.forename: Anja
authors.initials: A
authors.lastname: Pfenninger
authors.forename: Anke
authors.initials: A
authors.lastname: Tönjes
authors.forename: Matthias
authors.initials: M
authors.lastname: Blüher
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D050903:Nicotinamide N-Methyltransferase / Q000378:metabolism*; D009765:Obesity / Q000097:blood*; D012333:RNA, Messenger / Q000378:metabolism*; D050151:Subcutaneous Fat / Q000201:enzymology*
chemical_list: D012333:RNA, Messenger; D009536:Niacinamide; D050903:Nicotinamide N-Methyltransferase